• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications

    Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications

  2. Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

    Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

  3. Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance

    Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance

  4. Vaunted Ebola Vaccine Faces Questions

    Vaunted Ebola Vaccine Faces Questions

  5. 22nd Century Accepted to Present Proprietary Smoking Cessation Product at BIOCHINA Partnering Forum in Zhuhai, China

    22nd Century Accepted to Present Proprietary Smoking Cessation Product at BIOCHINA Partnering Forum in Zhuhai, China

  6. Video of Mannatech’s Manapol Creation Process Available on Business Wire’s Website

    Video of Mannatech’s Manapol Creation Process Available on Business Wire’s Website

  7. UPDATE: Why drinking all those diet sodas may come back to haunt you later in life

    UPDATE: Why drinking all those diet sodas may come back to haunt you later in life

  8. UPDATE: Why drinking all those diet sodas may come back to haunt you later in life

    UPDATE: Why drinking all those diet sodas may come back to haunt you later in life

  9. Waters Corporation (NYSE: WAT) Reports First Quarter 2017 Financial Results

    Waters Corporation (NYSE: WAT) Reports First Quarter 2017 Financial Results

  10. FDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade

    FDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade

12345

©2017 Morningstar Advisor. All right reserved.